ReviewRSC advances2026
Itraconazole as a repurposed anti-cancer agent: focusing on synthesis, mechanisms of action and therapeutic insights.
Review in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer drug development faces significant challenges due to long timelines, stringent regulatory requirements, and high failure rates. Drug repurposing has emerged as an efficient strategy to accelerate the discovery of novel therapies. Itraconazole (ITZ), a triazole antifungal approved in 1992 and widely used for over 30 years, has recently shown promising anticancer activity. This review provides a comprehensive overview of ITZ in cancer therapy, covering its synthesis and chemistry-based perspectives, mechanisms of action including angiogenesis inhibition and modulation of key signaling pathways, and preclinical and clinical evidence of its efficacy against various cancers. In addition, we discuss comparative drug delivery systems to optimize its therapeutic potential and summarize the latest studies from 2021 to 2025 highlighting its role as a potential anticancer agent. By consolidating current knowledge, this review aims to guide researchers and clinicians in exploring ITZ as a repurposed therapeutic option for cancer treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.